We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Synergy Pharmaceuticals, Inc. (MM) | NASDAQ:SGYPD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.45 | 0 | 00:00:00 |
From Nov 2019 to Nov 2024
Synergy Pharmaceuticals Inc. (SGYP) on Friday confirmed its previously announced agreement with Bausch Health Companies Inc. (BHC) has been approved by the U.S. Bankruptcy Court for the Southern District of New York.
The sale of Synergy's assets, including all rights to Trulance, dolcanatide and related intellectual property, is now expected to close on or about March 5.
Bausch Health Companies on Tuesday said it was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals, which voluntarily filed for bankruptcy in December, for approximately $195 million in cash and the assumption of certain assumed liabilities.
The auction scheduled for Feb. 26 didn't go forward, Synergy said, as no party submitted a higher and better bid.
Write to Aaron Rennie at aaron.rennie@wsj.com
(END) Dow Jones Newswires
March 01, 2019 18:58 ET (23:58 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Synergy Pharmaceuticals, Inc. (MM) Chart |
1 Month Synergy Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
